AKT1 and lung cancer: HSP90AA1, one of the HSP90 isoforms, showed a significant correlation with survival time in lung cancer patients by inhibiting the AKT1 and ERK pathways (Niu et al., 2021) and was upregulated in colorectal cancer (Szczuka et al., 2021).